NCT02711137 2025-10-21Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced MalignanciesIncyte CorporationPhase 1/2 Terminated137 enrolled 31 charts
NCT04551053 2025-10-02To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)Incyte CorporationPhase 3 Terminated177 enrolled 15 charts
NCT02718300 2024-05-01A Study of INCB050465 in Combination With Ruxolitinib in Subjects With MyelofibrosisIncyte CorporationPhase 2 Terminated74 enrolled 40 charts
NCT03878524 2024-03-04Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialOHSU Knight Cancer InstitutePhase 1 Terminated2 enrolled
NCT04480086 2023-08-29Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With MyelofibrosisAbbViePhase 1 Terminated1 enrolled
NCT02587598 2021-12-08Study of INCB053914 in Subjects With Advanced MalignanciesIncyte CorporationPhase 1/2 Terminated97 enrolled 40 charts